308 related articles for article (PubMed ID: 36136330)
1. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
[TBL] [Abstract][Full Text] [Related]
2. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care.
De Silva DL; Stafford L; Skandarajah AR; Sinclair M; Devereux L; Hogg K; Kentwell M; Park A; Lal L; Zethoven M; Jayawardana MW; Chan F; Butow PN; James PA; Mann GB; Campbell IG; Lindeman GJ
Med J Aust; 2023 May; 218(8):368-373. PubMed ID: 37005005
[TBL] [Abstract][Full Text] [Related]
3. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O
JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552
[TBL] [Abstract][Full Text] [Related]
6. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
8. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
[TBL] [Abstract][Full Text] [Related]
9. Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.
Acevedo F; Walbaum B; Camus M; Manzor M; Muñiz S; Medina L; Petric M; Reyes P; Domínguez F; Puschel K; Merino T; Bravo ML; Pinto MP; Ibáñez C; Hughes K; Sánchez C
Breast Cancer Res Treat; 2023 Jun; 199(2):363-370. PubMed ID: 36988750
[TBL] [Abstract][Full Text] [Related]
10. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM
JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204
[TBL] [Abstract][Full Text] [Related]
11. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE
Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347
[TBL] [Abstract][Full Text] [Related]
12. Germline Genetic Testing After Cancer Diagnosis.
Kurian AW; Abrahamse P; Furgal A; Ward KC; Hamilton AS; Hodan R; Tocco R; Liu L; Berek JS; Hoang L; Yussuf A; Susswein L; Esplin ED; Slavin TP; Gomez SL; Hofer TP; Katz SJ
JAMA; 2023 Jul; 330(1):43-51. PubMed ID: 37276540
[TBL] [Abstract][Full Text] [Related]
13. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
14. Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making.
Shelton C; Ruiz A; Shelton L; Montgomery H; Freas K; Ellsworth RE; Poll S; Pineda-Alvarez D; Heald B; Esplin ED; Nielsen SM
Ann Surg Oncol; 2024 Jan; 31(1):325-334. PubMed ID: 37814187
[TBL] [Abstract][Full Text] [Related]
15. Germline whole genome sequencing in adults with multiple primary tumors.
Wang Y; Ding Q; Prokopec S; Farncombe KM; Bruce J; Casalino S; McCuaig J; Szybowska M; van Engelen K; Lerner-Ellis J; Pugh TJ; Kim RH
Fam Cancer; 2023 Oct; 22(4):513-520. PubMed ID: 37481477
[TBL] [Abstract][Full Text] [Related]
16. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
18. Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition.
Kamihara J; Zhou J; LaDuca H; Wassner AJ; Dalton E; Garber JE; Black MH
Cancer Med; 2022 Apr; 11(8):1745-1752. PubMed ID: 35174967
[TBL] [Abstract][Full Text] [Related]
19. Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives.
Heald B; Pirzadeh-Miller S; Ellsworth RE; Nielsen SM; Russell EM; Beitsch P; Esplin ED; Nussbaum RL; Pineda-Alvarez DE; Kurian AW; Hampel H
J Natl Cancer Inst; 2024 Feb; 116(2):334-337. PubMed ID: 37756683
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
Yap TA; Ashok A; Stoll J; Mauer E; Nepomuceno VM; Blackwell KL; Garber JE; Meric-Bernstam F
JAMA Netw Open; 2022 May; 5(5):e2213070. PubMed ID: 35594047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
